

HIGHLIGHTS

- Jean Georges announces upcoming retirement and plans for succession3
- Our European Parliament Lunch Debate focuses on “Dementia as a Priority in EU Policies”3
- Biogen announces topline results from Phase II CELIA study of tau-targeting therapy diranersen...16
- Submit your work for our Anti-Stigma Award by 26 June!6
- #36AEC Early Bird registration will close on 30 June!7

CONTENTS

WELCOME	1
IN MEMORIAM	2
ALZHEIMER EUROPE	2
SPONSORS OF THE MONTH	7
AE NETWORKING	8
EU PROJECTS	10
MEMBERS OF THE EUROPEAN ALZHEIMER'S ALLIANCE.....	11
EU DEVELOPMENTS	12
POLICY WATCH.....	13
SCIENCE WATCH	14
MEMBERS' NEWS	18
DEMENTIA IN SOCIETY	23
LIVING WITH DEMENTIA	24
AE CALENDAR 2026.....	24
CONFERENCES 2026-2027	25

WELCOME



I am very sad to start this month's editorial with the news that our friend and former colleague Hilary Doxford has passed away. Hilary was previously a member of the European Working Group of People with Dementia (EWGPWD) and served as one of the group's first Vice-Chairpersons. Our deepest condolences go to her husband Peter, her family, friends and colleagues.

At the start of the month, the team decamped to Brussels for a series of meetings, including a Board meeting, a roundtable with sponsors, a lunch debate on “Dementia as a Priority in EU Policies” hosted by European Alzheimer's Alliance Co-Chair Hilde Vautmans MEP, a Public Affairs meeting with members, and a meeting of the EWGPWD.

During our Brussels meetings, I shared my plans to retire at the end of this year, after 30 years leading the organisation. Our current Director for Research, Angela Bradshaw, will be my successor as of 1 January 2027. In the meantime, to ensure a smooth handover, Angela will be my deputy, as of 1 July. Her role leading the research team will pass to Cindy Birk. Congratulations to them both on their new roles! I am not leaving just yet, however, as I will stay in my current position until 2027 and will take the opportunity of my final Alzheimer Europe Conference as Executive Director, in Dublin this October, to say goodbye to everyone!

Speaking of the conference, don't forget that the Early Bird registration period closes at the end of June, so please register now, to benefit from the reduced fees! Also, a reminder

that our Anti-Stigma Award applications close on 26 June, so please ensure that any submissions for the Award, this year aimed at recognising a European initiative or artist that brings together music and dementia, are in on time!

On the research front, I am pleased to share news from Biogen which has announced topline results from its Phase II CELIA study evaluating diranersen, an investigational therapy targeting tau, in people with early Alzheimer's disease (AD). According to the company, the results provide evidence showing both reduction in Tau pathology and cognitive benefit in early AD.

Of course, not all dementias are caused by AD and with this in mind, we held a session of our online workshop series the “Alzheimer's Association Academy”, with expert speakers discussing dementia with Lewy-bodies, Parkinson's disease dementia, frontotemporal dementia and childhood dementia.

In closing, I would like to thank colleagues at the Luxembourg Centre for Systems Biomedicine (LCSB) at the University of Luxembourg, where our team went to learn more about the centre's work in neurodegenerative research across a wide range of disciplines. As one of the University of Luxembourg's interdisciplinary research centres, the LCSB covers neuroscience, genetics, bioinformatics, computational biology, and clinical research, with a particular focus on neurodegenerative diseases such as Alzheimer's and Parkinson's. The visit was part of an exchange between our two organisations, and we look forward to welcoming the LCSB team to our offices in June, to learn more about our work.

Jean Georges, Executive Director

Alzheimer Europe Board

Chairperson: Maria do Rosário Zincke Dos Reis (Portugal); Vice-Chairperson: Mario Possenti (Italy); Honorary Secretary: Lorène Gilly (France); Honorary Treasurer: Marco Blom (Netherlands); Members: Stefanie Becker (Switzerland), René Friederici (Luxembourg), Andy Heffernan (Ireland), Martina Máttová (Czechia), Mary-Frances Morris (United Kingdom - Scotland), Kevin Quaid, Chairperson of the European Working Group of People with Dementia (Ireland), Trevor Salomon, Chairperson of the European Dementia Carers Working Group (United Kingdom - England), Katarina Suomu (Finland), Jochen René Thyrian (Germany).

Alzheimer Europe Staff

Executive Director: Jean Georges; Communications Officers: Kate Boor Ellis and Margarita Reyes; Conference Coordinator: Isabelle Collet; Events Coordinator: Cristina Pencea; Policy Officer: Owen Miller; Administrative and Conference Assistant: Eva Hueso; Project Administrator: Daniela Janeva; Director for Public Involvement and Ethics: Dianne Gove; Public Involvement Lead: Ana Diaz; Public Involvement Officers: Sarah Campill, Faye Forsyth and Soraya Moradi-Bachiller; Director for Research: Angela Bradshaw; Project Officers: Cindy Birk and Lukas Duffner.

IN MEMORIAM

10 MAY:

In Memoriam Hilary Doxford



We were deeply saddened to learn of the passing of our friend and former colleague Hilary Doxford, who died peacefully at home, with her husband Peter by her side, on Sunday 10 May.

Hilary joined the European Working Group of People with Dementia (EWGPWD) in October 2014 and served as one of the group's first Vice-Chairpersons, until 2016. She was an active and well-loved member of the group, nominated by the Alzheimer's Society (UK). The team at Alzheimer Europe has very fond memories of Hilary and of her important contributions to the work of the EWGPWD, and as a regular speaker and contributor to our conferences and meetings. She had a real passion for advocacy and campaigned tirelessly for a better world for people affected by dementia.

Hilary was a very special person, who brought warmth, positivity and humour to those around her. She touched the lives of so many people, and we feel truly privileged to have had the opportunity to meet and work with her. We will always remember her with great affection.

We send our deepest condolences to Hilary's husband Peter, as well as to her family, friends and to all who knew her.

ALZHEIMER EUROPE

4 MAY:

Alzheimer Europe Board meets in Brussels

The Alzheimer Europe Board held a meeting on 4 May in Brussels (Belgium). Jean Georges, Executive Director, Angela Bradshaw, Director for Research, Dianne Gove, Director for Public Involvement and Ethics, and Ana Diaz, Public Involvement Lead, were also in attendance.

Board members and the Alzheimer Europe management team discussed the organisation's Annual Conference and other events and meetings, several EU project applications, finances for 2026, membership applications, the organisation's upcoming position paper on anti-amyloid treatments, partnerships with other organisations, some staff changes, and then looked ahead to 2027 at some of the planned activities for the organisation.

The next Board meeting will take place on 29 June at our offices in Luxembourg.

5 MAY:

Alzheimer Europe hosts a Company Round Table meeting with sponsors



All corporate sponsors have provided sponsorship to support educational and healthcare related activities and have no input in the content or activities produced by Alzheimer Europe.

On 5 May 2026, Alzheimer Europe was pleased to welcome representatives of its corporate sponsors to a Company Round Table meeting in Brussels (Belgium), together with Alzheimer Europe staff. The meeting was chaired by Jean Georges, Executive Director.

Cindy Birck, Project Officer, presented some recent clinical trial developments and gave an update on our [Clinical Trials Watch](#) service. She was followed by Lukas Duffner, Project Officer, who discussed our work to support research participation and data sharing, including our recent [data sharing report](#). Up next was a presentation on regulatory and HTA challenges for new anti-amyloid treatments, given by Stéphane Epelbaum, International Leader Neuroscience, Eli Lilly. Ana Diaz, Public Involvement Lead was next, with an overview of our Public Involvement activities, and Jean Georges closed out

the meeting, sharing some updates on AE's Annual Conference and other activities, meetings and projects in 2026, as well as announcing some organisational changes.

5 MAY:

Alzheimer Europe Executive Director Jean Georges announces upcoming retirement and plans for succession at end of 2026



On 5 May 2026, during a meeting with Alzheimer Europe's sponsors and national member associations, Jean Georges, the organisation's Executive Director (pictured, left), announced his planned retirement at the end of this year.

Jean has been leading Alzheimer Europe since 1996 and after 30 years at the helm, he will step down and hand the reins to our current Director for Research, Angela Bradshaw (pictured, right). To ensure a smooth succession, Angela will first step into the role of Deputy Executive Director of Alzheimer Europe on 1 July and will then become Executive Director as of 1 January 2027.

When Angela becomes Deputy Executive Director on 1 July, she will vacate her position as head of the research team and will be replaced by Cindy Birck, who will become Research Lead.

5 MAY:

Alzheimer Europe hosts a European Parliament Lunch Debate on "Dementia as a Priority in EU Policies"

On 5 May, Alzheimer Europe held a lunch debate in the European Parliament in Brussels (Belgium), entitled "Dementia as a Priority in EU Policies", attended by national member organisations, the European Working Group of People with Dementia (EWGPWD), civil society representatives, industry partners and policy makers. Almost 90 people were in attendance, including seven Members of the European Parliament (MEPs): Hilde Vautmans MEP (Belgium), Nina Carberry MEP (Ireland),

Maria Guzenina MEP (Finland), Marit Maij MEP (Netherlands), Nikos Papandreu MEP (Greece), Maria Zacharia MEP (Greece) and Tomáš Zdechovský MEP (Czechia).

The meeting was hosted by Co-Chair of the European Alzheimer's Alliance (EAA), Hilde Vautmans MEP (Belgium). She opened by sharing her own personal experience as a daughter whose father had Alzheimer's disease, highlighting that the diagnosis often takes too long, even when family members begin to recognise signs and symptoms of the condition. She spoke about the need for dementia to be prioritized at a European level, especially in light of the figures showing the increase in the number of people living with dementia in the decades to come.

Owen Miller, Policy Officer, Alzheimer Europe, presented on the prevalence of dementia in Europe, outlining the findings of the report published earlier in the year. He highlighted some of the key findings of the report, including the changes in estimated prevalence rates by sex and age range, as well as explaining that 9.1 million people have dementia in EU27 countries in 2025, which is expected to increase to 14.3 million by 2050, despite the declining population in Europe. He closed his presentation with a call to action for decision makers, highlighting that inaction risks worsening the challenges faced by people living with dementia, noting the opportunity presented by the ongoing negotiations of the next EU Multiannual Financial Framework (MFF).

The following presentation was given by Ledia Lazeri, Regional Adviser, Mental Health Flagship, World Health Organization (WHO) Regional Office for Europe, who presented on the Global Action Plan on dementia, as well as relevant global and European developments. She highlighted the WHO's Global Action Plan on the Public Health Response to Dementia 2017-2025, which has been extended to 2031. She provided data to show that the goals of the plan were not on course to be met and that whilst Europe was doing better than other WHO Regions in many areas, it still was not meeting the targets. Additionally, she highlighted a number of resources the WHO had produced to support governments in the development of dementia policy, including in relation to awareness raising, research etc.

Olga Martinez de Briones, Policy Officer, Disability Unit, DG Justice and Consumers, European Commission, presented on the place of dementia in European disability programmes and policies. She opened her presentation by noting that the EU Strategy on the Rights of Persons with Disabilities 2021-2030 was due to be updated, with a new version to be published the following day. She highlighted actions and legislative files undertaken in recent years by the European Commission, which have relevance for people with dementia, including the European Disability Card and the European Parking Card.

During the open discussion session, a number of MEPs in attendance reflected on their priorities around the future of dementia at an EU level.



MEP Carberry spoke of the rising number of people living with dementia and spoke of her commitment as a policy-maker to supporting work to prioritise dementia at a European level, including pushing for a dedicated research mission on dementia. Additionally, she spoke of the importance of development and implementation of prevention and risk reduction in dementia policies.

MEP Papandreou highlighted the increasing challenge to healthcare systems posed by the rising numbers of people living with dementia and the need for a focus on the risk factors associated with dementia. Additionally, he expressed the need to raise awareness and support to actively encourage people to volunteer and offer support for activities and services in the community.

MEP Zdechovský spoke of the importance of the cross-party nature of dementia as a policy issue and for concrete steps to be taken at an EU level. Additionally, he highlighted the progress in treatments, as well as the need for further research and collaboration.

Alzheimer Europe's Executive Director, Jean Georges, drew the session to a close by thanking the speakers and attendees, noting that the figures presented underscored the need for actions at a European level.

Alzheimer Europe thanks all MEPs, speakers, delegates and its Gold and Silver sponsors, for making this event possible.

5-6 MAY:

Alzheimer Europe hosts Public Affairs meeting in Brussels

Alzheimer Europe welcomed delegates, representing 23 national member associations from 21 different countries across Europe, to its Public Affairs meeting on 5 and 6 May 2026 in Brussels (Belgium). The meeting was also attended by staff from Alzheimer Europe and by a representative of the European Dementia Carers Working Group (EDCWG).

The agenda on 5 May began with a section on "Advocating for new AD treatments in Europe", moderated by Angela Bradshaw, Director for Research who started things off with a presentation on Alzheimer Europe's position paper on anti-

amyloid treatments, called "From European Commission approval to access in European countries". This was followed by a discussion with members and with some presentations on learnings from national activities and campaigns, with contributions from Wiesje van der Flier (Netherlands), Friederike de Maeyer (Austria), Jo Baxter (United Kingdom) and Štefanija Lukić Zlobec (Slovenia). Members were then given the floor to share some of their national activities, with presentations from Ofelya Kamavosyan (Armenia), René Thyrian (Germany), and Jana Strashevskva (North Macedonia).

The second day of the meeting began with a section on "Alzheimer's associations and other types of dementia" moderated by Soraya Moradi-Bachiller, Public Involvement Officer, and Angela Bradshaw. They spoke about PREDICTFTD, a new EU Project aimed at raising public awareness on fronto-temporal dementia. Following this first presentation of the day, Andy Heffernan (Ireland) gave some insights into "Experiences of national Alzheimer's associations on communicating on and advocating for other types of dementia and people affected by them".

Members were then given the floor to share some of their national activities, with presentations from Iryna Shevchenko (Ukraine), Katariina Suomu (Finland), Cormac Cahill (Ireland), Mary-Frances Morris (Scotland, United Kingdom), Friederike de Maeyer (Austria), Süslü Hatice Sertaç (Türkiye), Maria Kreger Karabova (Slovakia), Elka Stefanova (Serbia), Ourania Chatziroupi (Greece), Štefanija Lukić Zlobec (Slovenia), Edyta Ekwinska (Poland), Kristia Ivanova (Bulgaria).

Our next Public Affairs meeting is scheduled to take place on 30 June and 1 July in Luxembourg.

5-6 MAY:

European Working Group of People with Dementia meets in Brussels

On 5 and 6 May, members of the European Working Group of People with Dementia (EWGPWD) met in person in Brussels (Belgium), with 12 members travelling from across Europe accompanied by their supporters. The EWGPWD (2012) is composed entirely of people with dementia, nominated by their national Alzheimer associations who are member associations of Alzheimer Europe.

Over the two days, members engaged in a series of discussions on ongoing Alzheimer Europe activities and European dementia research initiatives. Topics included collaboration with the INTERDEM network and Alzheimer Europe's involvement in the PREDICTOM project. Members also contributed to discussions on Alzheimer Europe's [Clinical Trials Watch](#), on the Dementia in Europe Yearbook 2026 and the EWGPWD discussed their involvement during the plenary session at the upcoming Alzheimer Europe Conference in Dublin. The sessions were dynamic and highly productive, with members sharing personal experiences, perspectives and priorities with the Alzheimer Europe Public Involvement team, reinforcing

the importance of meaningful involvement of people with dementia in research and policy.

The consultations were facilitated by Dianne Gove (Director of Public Involvement and Ethics), Ana Diaz (Public Involvement Lead), Soraya Moradi-Bachiller (Public Involvement Officer), Sarah Campill (Public Involvement Officer) and Faye Forsyth (Public Involvement Officer). The Public Involvement team was joined for dedicated sessions by Cindy Birck (Project Officer), Owen Miller (Policy Officer) and Margarita Reyes (Communications Officer).

On 5 May, the EWGPWD attended a lunch debate at the European Parliament organised by Alzheimer Europe, entitled "Dementia as a Priority in EU Policies". The event brought together around 90 participants, including policymakers, civil society representatives and researchers. Seven Members of the European Parliament (MEPs) were in attendance: Hilde Vautmans (Belgium), Nina Carberry (Ireland), Maria Guzenina (Finland), Marit Maij (Netherlands), Nikos Papandreou (Greece), Maria Zacharia (Greece) and Tomáš Zdechovský (Czechia).

The debate highlighted the growing impact of dementia across Europe and the urgent need for coordinated EU action to improve diagnosis, care, research and support. Members of the EWGPWD and their supporters had the opportunity to connect directly with policymakers, including MEPs from their own countries, raising issues that reflect their lived experience and advocating for dementia to remain a European policy priority.

12 MAY:

Alzheimer Europe visits the Luxembourg Centre for Systems Biomedicine



On 12 May, Alzheimer Europe visited the Luxembourg Centre for Systems Biomedicine (LCSB) at the University of Luxembourg to learn more about their work in neurodegenerative research across a wide range of disciplines. As one of the University of Luxembourg's interdisciplinary research centres, the LCSB covers neuroscience, genetics, bioinformatics, computational biology, and clinical research, with a particular focus

on neurodegenerative diseases such as Alzheimer's and Parkinson's. The centre aims to advance the diagnosis, prevention, and treatment of these conditions, closely aligned with AE's mission and objectives.

During the exchange visit, the Alzheimer Europe team members Kate Boor Ellis, Sarah Campill, Ana Diaz, Dianne Gove, Lukas Duffner, Cindy Birck, and Margarita Reyes were welcomed by Prof. Michael Heneka, LCSB Director and Head of the Neuroinflammation group, who opened the meeting with a talk on "Targeting immune mechanisms in Alzheimer's disease."

He was then followed by Prof. Enrico Glaab, Head of the Biomedical Data Science group, who presented on 'Sex Differences in Alzheimer's Disease', exploring how the disease may affect men and women differently at the genetic level through studies of human brain tissue from AD patients and mouse models. The final talk was by Dr Tom Scheidt, Head of the Molecular Biophysics group on "Natural and Synthetic Aggregation Inhibitors",

The meeting concluded with a tour of the Neuroinflammation lab, led by Dr Wanda Grabon and Dr Clémence Tropis. The tour provided an excellent opportunity to gain insight into the advanced imaging and microscopy techniques used to study brain immune cells and to see how cutting-edge neuroscience research is being conducted day to day in Luxembourg.

In June, Alzheimer Europe will also welcome members of the LCSB for a reciprocal visit, where they will present their current EU project portfolio, their public involvement activities and explore a potential collaboration between research and patient advocacy in the field of dementia and brain health.

Learn more about the LCSB at: <https://www.uni.lu/lcsb-en/>

19 MAY:

European Dementia Carers Group meets online

The European Dementia Carers Working Group (EDCWG) brings together current and former carers of people with dementia from across Europe, providing a platform to ensure that carers' perspectives are reflected in Alzheimer Europe's activities.

On Tuesday, 19 May, members of the EDCWG met online to discuss a range of topics, including their involvement in the upcoming Alzheimer Europe Conference in Dublin (27-29 October 2026), the forthcoming end of the current term of the EDCWG and the re-nomination process for members. During the second part of the meeting, members reviewed the Alzheimer Europe Clinical Trials Watch webpage (<https://www.alzheimer-europe.org/research/clinical-trials>), which was first developed over a decade ago to provide a clear, accessible overview of clinical trials for people with dementia and their carers. The resource offers up-to-date, dementia-friendly information on clinical studies, including details

on the type of intervention, trial phase, recruitment status and participating countries, helping users better understand ongoing research and opportunities to take part. The discussion focused on how to further improve the resource to better meet the needs of its users.

The meeting was facilitated by Ana Diaz (Public Involvement Lead) and Sarah Campill (Public Involvement Officer) and chaired by EDCWG Chairperson Trevor Salomon (United Kingdom).

26 MAY:

Alzheimer Europe hosts a session of its Alzheimer's Association Academy entitled "Not all dementias are Alzheimer's disease"



On 26 May, Alzheimer Europe held a session of its online workshop series the Alzheimer's Association Academy, entitled "Not all dementias are Alzheimer's disease".

Our Academies are a popular series of online capacity-building workshops bringing together representatives of national Alzheimer's associations with members of the European Working Group of People with Dementia (EWGPWD) and European Dementia Carers Working Group (EDCWG), as well as representatives from pharmaceutical companies, to learn about dementia advocacy, care, policy, research and treatment.

Project Officer Cindy Birck chaired the session, welcoming close to 40 participants from 15 countries and two companies (Anavex and Bristol Myers Squibb), as well as several members of staff from Alzheimer Europe.

Speakers at the session included:

- Phil Angrave, a member of the EWGPWD, who shared his lived experience following a diagnosis of Dementia with Lewy-bodies (DLB), and of some of the difficulties he has faced, having a 'non-Alzheimer's type' of dementia
- Evelien Lemstra, a neurologist at Amsterdam University Medical Center (Amsterdam UMC), who shared a clinician's view on DLB as well as on Parkinson's disease dementia
- Harro Seelaar, a neurologist at Erasmus University Medical Center (Erasmus MC), who shared a clinician's view on Frontotemporal dementia (FTD)

- and Jill Carson, Consultant in Public Policy for Alzheimer Scotland, who discussed the recent policy report "Childhood dementia in Scotland 2025".

Following each of these informative and insightful presentations, there was ample opportunity for questions to the speakers.

We hope everyone enjoyed the session and we would like to say a huge thank you to all speakers and to our Gold and Silver sponsors, Bristol Myers Squibb, Eisai, Johnson & Johnson, Eli Lilly and Company, and Roche as well as to the European Union's Citizen's, Equalities, Rights and Values (CERV) programme, without whom our Academy sessions would not be possible.

31 MAY:

Submit your work to the 2026 Anti-Stigma Award before 26 June! Register for the ceremony now!

Submissions now open for the 2026 Anti Stigma Award!

Together with the Alzheimer Europe Foundation and our partners, we are proud to launch the 2026 call for the Anti-Stigma Award.

This year, we celebrate European initiatives and artists meaningfully combining **music and dementia** in projects that:

- Actively involve people living with dementia in musical activities
- Use music to challenge stigma
- Promote a positive, empowering image of dementia through musical performances

We welcome your submissions until 26 June 2026
An award ceremony will be held in Dublin on 28 October 2026.
Apply at www.alzheimer-europe.org/anti-stigma-award-2026

Alzheimer Europe Foundation, Lilly, Roche

This year, Alzheimer Europe, along with its partners, the Alzheimer Europe Foundation, Lilly and Roche, are pleased to recognise a European initiative or artist that brings together music and dementia through the 2026 Anti-Stigma Award. The call for submissions launched on 15 April and eligible entries include initiatives involving people with dementia in musical activities or songs or other musical productions aimed at addressing stigma and promoting a positive image of dementia. Interested initiatives/artists should send information on their work via the [application form](#) by 26 June. More information regarding the prizes and submission process can be found at: <https://www.alzheimer-europe.org/anti-stigma-award-2026>

Applications can be made by the artists themselves or by a nominating national Alzheimer's association. Organisations wishing to nominate an initiative or artist may do so but will need their written consent. The award is open to initiatives/artists established in a member country of Alzheimer Europe for contributions produced between 2021-2026. The awards together with a trophy will be presented at an award ceremony organised in Dublin on 28 October 2026. The travel and accommodation costs for the short-listed initiatives will be covered by Alzheimer Europe.

In addition, the Anti-Stigma ceremony will take place as part of a networking dinner for the 36th Alzheimer Europe conference. Separate registration is required for both conference delegates and ceremony-only attendees. Please register for the award ceremony here: <https://www.alzheimer-europe.org/conferences/2026-dublin/networking-dinner>

31 MAY:

**Early bird registration is open until 30 June!
Register now for #36AEC!**

As preparations are underway for the next Alzheimer Europe conference in beautiful Dublin, the early bird registration for the event is open only until 30 June! Take advantage of the early bird registration fees, where full registration includes access to all sessions, networking events, the exhibition hall, refreshments, and more. [Click here to register for #36AEC.](#) In addition, the Anti-Stigma ceremony will take place as part of a networking dinner for the 36th Alzheimer Europe conference. Separate registration is required for both conference delegates and ceremony-only attendees. Please register for



the award ceremony here: <https://www.alzheimer-europe.org/conferences/2026-dublin/networking-dinner> The conference will take place from 27 to 29 October 2026 in Dublin, Ireland at the Convention Centre Dublin. **Special rates** are available for people with dementia, carers and students. Visit the [conference website](#) to learn more about the organisers, travel information, accommodation options, and the venue. We look forward to seeing you in Dublin for #36AEC!

SPONSORS OF THE MONTH

Alzheimer Europe would like to express its gratitude to two new sponsors for its 2026 Annual Conference:



All corporate sponsors have provided sponsorship to support educational and healthcare related activities and have no input in the content or activities produced by Alzheimer Europe.

Read more about sponsorship opportunities here:

<https://www.alzheimer-europe.org/about-us/governance/finances/2025-sponsorship-opportunities>

AE NETWORKING

4 MAY	The Alzheimer Europe Board met (Brussels, Belgium)
5 MAY	Alzheimer Europe held a Company Round Table with sponsors (Brussels, Belgium)
5 MAY	Alzheimer Europe and the European Alzheimer's Alliance organised a European Parliament lunch debate on the topic of "Prioritising dementia in EU Policies" (Brussels, Belgium)
5-6 MAY	Alzheimer Europe organised a Public Affairs meeting with its members (Brussels, Belgium)
5-6 MAY	The European Working Group of People with Dementia held a meeting (Brussels, Belgium)
9-10 MAY	Dianne attended the Annual General Assembly of European Disability Forum online (Larnaca, Cyprus)
11-12 MAY	Angela participated in a Clinical Summit on amyloid-related imaging abnormalities, organised by the American Heart Association (Valkenburg, the Netherlands)
12 MAY	Alzheimer Europe visited the Luxembourg Centre for Systems Biomedicine (Esch, Luxembourg)
12 MAY	Owen attended a meeting of the European Care Alliance
15 MAY	Angela spoke at the ASK 2026 International Conference on Dementia organised by Spominčica Alzheimer Slovenia (Ljubljana, Slovenia)
18-20 MAY	Isabelle attended IMEX2026 (international trade show for the meetings & events industry) (Frankfurt, Germany)
19 MAY	The European Dementia Carers Working Group held an online meeting, facilitated by Ana and Sarah
18-19 MAY	The ENSURED consortium met online with a range of stakeholders from national Alzheimer's associations to present the project and explore synergies
19-20 MAY	Cindy and Soraya organised a meeting with the DORIAN GRAY Advisory Board members (Milan, Italy)
21 MAY	Jean and Angela joined an online meeting for CERV operating grant recipients, organised by the Disability Unit of DG JUST at the European Commission
26 MAY	Alzheimer Europe held a session of its online Alzheimer's Association Academy, titled "Not all dementias are Alzheimer's disease"
27 MAY	Jean met with Alzheimer Switzerland
27 MAY	Cindy attended the online AI-Mind review meeting
28 MAY	Jean and Ana met with Fundació Pasqual Maragall
28 MAY	Jean attended an OECD webinar on "Policies for people with dementia across OECD countries"

Understanding the scale of dementia in Europe



Celebrating 50 editions of Dementia in Europe

Making dementia a European priority in policy and research, giving a voice to people with lived experience



Help us give a voice to people with dementia



[Donate](#)

@AlzheimerEurope
Non-profit NGQ, making dementia a European priority.

- [Learn about the Prevalence of Dementia in Europe 2025 Report](#)
- [Check out the Dementia in Europe Yearbook 2025](#)
- [Join our Public Involvement Pool](#)
- [Help us give a voice to people living with dementia](#)
- [Submit an abstract to the #38AEC Conference in Dublin](#)
- [Subscribe to our Newsletter](#)

[w](#) [in](#) [f](#) [ig](#) [yt](#) [en](#) [jd](#)

Join AlzheimerEurope on Linktree

Cookies Preferences - Report - Privacy - Explore

EU PROJECTS

19 MAY:

Members of the DORIAN GRAY Public Involvement Board participate in a face-to-face consultation



On 19–20 May, the DORIAN GRAY Public Involvement Board met in person in Milan for a face-to-face meeting with the project’s research team. The meeting provided a valuable opportunity for members and researchers to exchange ideas, experiences and feedback in a collaborative and engaging environment.

During the meeting, members of the Public Involvement Board had the opportunity to test the exergames developed within the DORIAN GRAY project. Discussions focused on how comfortable participants felt when interacting with the games, as

well as how engaging and motivating the exergame experience was overall. In another interactive session, members were given a smartphone to test the project’s digital coach. This hands-on activity allowed participants to explore the functionality and usability of the digital coaching system and to share their impressions directly with the research team.

The meeting marked an important milestone for the project, as it was the first time that members of the DORIAN GRAY Public Involvement Board and the research team met in person. Members who attended the session participated actively and provided insightful feedback to support the further improvement of the DORIAN GRAY app and exergames, which aim to promote healthy ageing and address the link between cardiovascular disease and cognitive impairment. An online follow-up meeting will be organised in the coming weeks, during which researchers will provide feedback on the discussions held in Milan and explain how contributions from members have helped improve the platform and the games.

The meeting was organised by Alzheimer Europe, which leads the Public Involvement work within the project, and was represented by Soraya Moradi-Bachiller and Cindy Birck, alongside researchers from several project partner organisations: Nicola Francesco Lopomo, Marco Loddo from Politecnico di Milano, Leonardo Angelini, Benedetta Giachetti, Ugo Eb-Levadoux, Arianna Boldi from Haute École Spécialisée de Suisse Occidentale, and Erik Berglund and Aseel Berglund from Liopep AB.

The project partners would like to extend their heartfelt gratitude to all members of the DORIAN GRAY Public Involvement Board for their engagement, commitment and invaluable contributions to the project.

Further information about the project can be found on the website: <https://www.doriangray-horizon.eu/>. This project has received funding from the European Union’s Horizon Europe research and innovation programme under Grant Agreement number 101156266.

EU project acknowledgements



A number of the projects in which Alzheimer Europe is a project partner receive funding from Horizon 2020, Horizon Europe, the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking (JU), or the Innovative Health Initiative (IHI) JU. Projects funded through the IMI2 or IHI JU receive support from EU Research & Innovation programmes, as well as industry federations and other contributing partners. Please visit the project website(s) listed below for specific details on the organisations, federations and funders providing support for individual projects.

Several projects have also received funding through:



Please see our website, to find out more about each project, its funding, and to explore the project websites: <https://www.alzheimer-europe.org/our-work/current-work>

MEMBERS OF THE EUROPEAN ALZHEIMER'S ALLIANCE



Currently, the total number of MEPs in the European Alzheimer's Alliance (EAA) stands at **89**, representing **22** Member States of the European Union and seven out of eight political groups in the European Parliament. Alzheimer Europe is grateful to the Co-Chairs of the EAA: Nina Carberry (EPP, Ireland); Tilly Metz (Greens/EFA, Luxembourg); Romana Jerković (S&D, Croatia); Sirpa Pietikäinen (EPP, Finland);

Vladimir Prebilič (Greens/EFA, Slovenia); Hilde Vautmans (Renew Europe, Belgium) and Dainius Žalimas (Renew Europe, Lithuania) for their leadership and for hosting the organisation's European Parliament lunch debates on dementia. Alzheimer Europe would also like to thank the following MEPs for their support of the EAA:

Belgium: Kathleen van Brempt (S&D); Johan Van Overtveldt (ECR); Hilde Vautmans (Renew Europe). **Bulgaria:** Radan Kanev (EPP); Andrey Kovatchev (EPP); Ilhan Kyuchyuk (Renew Europe); Tsvetelina Penkova (S&D); Kristian Vigenin (S&D). **Croatia:** Biljana Borzan (S&D); Romana Jerković (S&D); Tonino Picula (S&D); Tomislav Sokol (EPP). **Cyprus:** Costas Mavrides (S&D). **Czechia:** Ondřej Dostál (NI); Tomáš Zdechovský (EPP). **Denmark:** Kira Marie Peter-Hansen (Greens/EFA); Christel Schaldemose (S&D). **Estonia:** Urmas Paet (Renew Europe). **Finland:** Maria Guzenina (S&D, Finland); Merja Kyllönen (The Left); Sirpa Pietikäinen (EPP). **France:** François-Xavier Bellamy (EPP); Mélissa Camara (Greens/EFA); Laurent Castillo (EPP); David Cormand (Greens/EFA); Marie Dauchy (PFE); Christophe Gomart (EPP); Catherine Griset (PFE); Céline Imart (EPP); Isabelle Le Callennec (EPP); Nadine Morano (EPP); Philippe Olivier (PFE); Mounir Satouri (Greens/EFA); Majdouline Sbai (Greens/EFA); Marie Toussaint (Greens/EFA). **Germany:** Alexandra Geese (Greens/EFA); Erik Marquardt (Greens/EFA); Angelika Niebler (EPP); Manuela Ripa (Greens/EFA); Terry Reintke (Greens/EFA). **Greece:** Tsiodras Dimitrios (EPP); Emmanouil (Manolis) Kefalogiannis (EPP); Nikos Papandreou (S&D); Elissavet Vozemberg-Vrionidi (EPP). **Hungary:** Tamás Deutsch (PFE); Enikő Győri (PFE); Kinga Gál (PFE); György Hölvényi (EPP); András Kulja (EPP). **Ireland:** Barry Andrews (Renew Europe); Lynn Boylan

(The Left); Nina Carberry (EPP); Luke 'Ming' Flanagan (NI); Billy Kelleher (Renew Europe); Seán Kelly (EPP); Aodhán Ó Ríordáin (S&D); Maria Walsh (EPP). **Italy:** Brando Benifei (S&D); Caterina Chinnici (EPP); Carlo Fidanza (ECR); Aldo Patriciello (PFE). **Lithuania:** Vytenis Povilas Andriukaitis (S&D); Petras Auštrevičius (Renew Europe); Vilija Blinkevičiūtė (S&D); Liudas Mažylis (EPP); Dainius Žalimas (Renew Europe). **Luxembourg:** Marc Angel (S&D); Charles Goerens (Renew Europe); Tilly Metz (Greens/EFA); Isabel Wiseler-Lima (EPP). **Poland:** Elżbieta Katarzyna Łukacijewska (EPP); Michał Szczerba (EPP); Anna Zalewska (ECR). **Portugal:** Marta Temido (S&D); Catarina Martins (The Left). **Romania:** Vlad Vasile-Voiculescu (Renew Europe). **Slovenia:** Matjaž Nemeč (S&D); Irena Joveva (Renew Europe); Vladimir Prebilič (Greens/EFA); Marjan Šarec (Renew Europe); Romana Tomc (EPP); Milan Zver (EPP). **Spain:** Rosa Estaràs Ferragut (EPP); Juan Fernando López Aguilar (S&D); Idoia Mendia (S&D); Diana Riba i Giner (Greens/EFA); Ana Miranda Paz (Greens/EFA). **Sweden:** Pär Holmgren (Greens/EFA); Jonas Sjöstedt (S&D).

EU DEVELOPMENTS



European Parliament

5 MAY:

SANT Committee Opinion calls for dedicated health funding in the next EU budget

On 5 May, European Parliament SANT Committee adopted an Opinion for the IRTE Committee, relating to European Competitiveness Fund (ECF), as part of the ongoing negotiations on the Multiannual Financial Framework (MFF), the next seven-year cycle of the EU budget.

The Opinion underlined the importance of ensuring EU support for public health priorities within the ECF, including equitable access to medicines, prevention, health literacy, support for civil society organisations working in health, patient rights, patient safety. It also called for a strong dedicated funding for public health activities. As part of this it calls on the Commission to consider the possibility of a dedicated EU4Health programme within the ECF.

Additionally, amendments proposed by the Opinion call for support for NGOs contributing to prevention, health promotion and patient engagement, as well as demanding that the Commission present a roadmap towards a coherent Union framework for health financing, across the domains of programmes including Horizon Europe, EU4Health, Digital Europe etc.

The full text of the opinion is available at:

https://www.europarl.europa.eu/doceo/document/SANT-AD-784244_EN.pdf



6 MAY:

European Commission updates strategy on the rights of persons with disabilities

On 6 May, the European Commission adopted the Communication "Enhancing the strategy for the rights of persons with

disabilities up to 2030", updating the 2021-2030 Strategy for the Rights of persons with disabilities, at its halfway point.

Key points within the updated strategy include:

1. Support for the creation of national and local independent living centres, better monitoring of deinstitutionalisation processes in Member States.
2. Consideration of the occupational safety and health risks faced by workers with disabilities in the forthcoming Quality Jobs Act.
3. Commitment to study decision-making regimes and legal capacity legislation in the Member States.
4. Guidelines on procedural accommodation in accessing justice.
5. Commitment to publish a report on housing conditions of persons with disabilities across the EU.
6. An undertaking on quantifying the extra cost of living with a disability.

The European Disability Forum (EDF) has expressed disappointment with regards to some elements of the strategy including:

- A lack of new legislative initiatives.
- A lack of clear measures to meet the European Union's obligation under the UN Convention on the Rights of Persons with Disabilities (UNCRPD)
- Too great a focus on studies, preparatory work and already foreseen actions than on adopting new legislative and funding initiatives.

The updated strategy is available at:

https://commission.europa.eu/strategy-and-policy/policies/justice-and-fundamental-rights/disability/enhancing-strategy-rights-persons-disabilities-2030_en

EDF's position on the new strategy is available at:

<https://www.edf-feph.org/update-of-eu-disability-rights-strategy-lacks-ambition-to-advance-our-rights/>

12 MAY:

Council and Parliament agree position on cross-border protections for vulnerable adults

On 12 May, the Council and the European Parliament agreed on new rules to guarantee the rights of adults who need protection or support in cross-border situations. This includes rights related to the sale of property, medical care or relocation to another country.

The new law will protect the rights of adults who are no longer able to make decisions without some support – for example, those with age-related conditions like Alzheimer’s disease being supported by a family member or other representative.

Additionally, the regulation broadly aligns EU law in this area with international rules set out under the Hague Protection of Adults Convention, aiming to safeguard the autonomy of vulnerable adults, including their freedom to make their own choices, when moving within the EU.

Specifically, the new rules determine which court is competent to take protection measures in a cross-border case, which law applies, and the conditions for recognition and enforcement of measures or powers of representation established abroad.

Once the text has been finalised and formally approved by the co-legislators, the new legislation will enter into force 20 days after its publication in the EU’s official journal. The measures will then start progressively entering into application as of 24 months later.

Further information on the new legislation is available at:

<https://www.consilium.europa.eu/en/press/press-releases/2026/05/12/council-and-parliament-strike-deal-on-new-eu-rules-to-protect-vulnerable-adults/>

POLICY WATCH

27 MAY:

Members of the Greek Parliament and Greek MEPs participate in a Working Group for Dementia



Dementia is one of the most critical, complex, and rapidly growing public health and social cohesion challenges at both national and European levels. Its impact extends beyond healthcare, affecting the

sustainability of health and social care systems, public policy, and the overall quality of life of patients and caregivers. Recognising the urgency of this issue, Alzheimer Europe convened the European Alzheimer’s Alliance (EAA), a group of Members of the European Parliament dedicated to promoting dementia as a European priority. Greek MEPs have actively participated in the EAA over the years.

The Panhellenic Federation of Alzheimer Disease and Related Disorders, a member of Alzheimer Europe, in line with this initiative, the implementation of the Greek National Action Plan for Dementia and Alzheimer’s Disease, as well as broader European strategies on mental health, ageing, and non-communicable diseases, decided to organise a Working Group for Dementia. This Working Group consists of Members of the Greek Parliament and Greek MEPs. The initiative aims to

strengthen parliamentary awareness, encourage the exchange of best practices, and support evidence-based policy-making on dementia.

The group has already held five online meetings since January 2026, coordinated by Professor Emerita of Medicine at Aristotle University of Thessaloniki, Magda Tsolaki, President of the Panhellenic Federation of Alzheimer Disease and Related Disorders and member of the National Observatory for Dementia. The meetings focused on prevention, diagnosis, and treatment developments, support for caregivers, new Alzheimer’s therapies, the National Strategic Plan for Dementia, and the creation of dementia care structures in Greece.

The initiative has already produced tangible results. Parliamentary questions concerning the support for dementia patients and caregivers have been submitted to the Hellenic Parliament, while two Greek MEPs expressed their intention to join the European Alzheimer’s Alliance. The active participation of 15 politicians (ministers, MPs, MEPs, and their representatives) demonstrates the growing recognition that dementia requires coordinated national and European action supported by reliable scientific evidence.

SCIENCE WATCH

23 APRIL:

Migraine and the risk of dementia in the general population



In a recent article, Cevdet Acarsoy, Daniel Bos, Sanne S. Mooldijk, M. Arfan Ikram, M. Kamran Ikram focused on the relationship between migraine and the risk of developing dementia, addressing a debated question in the field: does migraine constitute a risk factor for, or potentially protect against, later-life neurodegeneration?

The researchers conducted a prospective, population-based cohort study using data from the Rotterdam Study, including 6,888 participants. Migraine status was assessed between 2006 and 2011 through validated questionnaires. Participants were subsequently followed for a median of 9.4 years. Dementia cases were identified via in-person cognitive assessments and linkage to medical records, allowing for robust diagnostic classification. Statistical analyses were performed using Cox proportional hazards models to evaluate associations between migraine and incident dementia, while adjusting for potential confounders.

Overall, 15.1% of participants reported migraine at baseline, and during follow-up, 491 individuals developed dementia, of whom the majority (77.2%) were diagnosed with Alzheimer's disease. Contrary to some earlier assumptions, migraine was associated with a reduced risk of dementia (hazard ratio [HR] 0.70, 95% CI 0.51–0.95) and Alzheimer's disease specifically (HR 0.58, 95% CI 0.40–0.85). These findings suggest that migraine is not linked to an increased risk of cognitive decline and may, in fact, be associated with a lower likelihood of developing dementia.

In conclusion, the study results challenge previous hypotheses linking migraine to cognitive decline mechanisms, instead indicating a possible protective association. However, the underlying mechanisms remain unclear. The authors highlight the need for further longitudinal research incorporating biomarkers and neuroimaging to disentangle potential biological effects from methodological or selection-related factors.

<https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71386>

28 APRIL:

Annovis publishes Phase II/III Alzheimer's trial results

On 28 April, Annovis Bio announced the publication of new Phase II/III clinical trial findings for its investigational oral therapy buntanetap in the peer-reviewed journal *Nature NPJ Dementia*.


The randomised, double-blinded and placebo-controlled study evaluated three doses of buntanetap (7.5 mg, 15 mg and 30 mg) over 12 weeks in 351 people with mild to moderate Alzheimer's disease (AD). Results showed that the treatment was safe and well tolerated across all disease stages and dose levels, including in ApoE4 carriers, a population considered at higher genetic risk for AD. The analyses also demonstrated statistically significant, dose-dependent improvements in cognition, measured using ADAS-Cog11, in pTau217 biomarker-positive participants with early AD.

The findings support the company's ongoing pivotal Phase III trial in early AD, which has enrolled approximately 80% of participants to date. The study is designed to assess both symptomatic and potential disease-modifying effects of buntanetap over 6 and 18 months, respectively.

<https://doi.org/10.1038/s44400-026-00073-z>

4 MAY:

Survey reveals patient views on blood-based biomarker test use in primary care to detect Alzheimer's disease



A large cross-sectional survey of 572 adults conducted in the United States, examining attitudes towards Alzheimer's disease blood-based biomarkers (BBB) testing, has been published in the journal *Alzheimer's and Dementia*. The survey was distributed to participants in three ongoing clinical trial or cohort studies (the C3 observation cohort study, the MidCog study and the LitCog study), who had various medical condi-

tions, and who had agreed to participate in future research endeavours. The survey was completed digitally, before starting, participants were provided with brief information about BBMs and their potential use in the primary care setting. The survey posed questions about the following categories: awareness and attitudes, facilitators and barriers to testing, and anticipated impact of receiving positive results.

In terms of awareness and attitudes, the survey reported that: 1) most people were unfamiliar with BBB tests (83.7% indicated unfamiliarity); 2) very few people had undertaken a BBB test in real life (n=10, 1.8%); 3) most considered it 'very important' to offer BBB tests in the context of memory or thinking problems (76.8%); 85% would be willing to undergo testing if recommended by their primary care provider. Interestingly, fewer people (60.4%) felt it was very important to offer BBB tests to 'any adult aged over 65 years'. In the category 'facilitators and barriers', the most endorsed facilitators were informed care (94.2%), insurance cover (88.5%) comprehensive education (88.5%) and ease of use (88.1%); common barriers were costs (49.3%), concerns about stigma (24.2%), and fear of a positive result (21.7%). When it came to anticipating impact, 87% indicated they would be likely to take steps to improve brain health, and 70% anticipated emotional distress. The authors also performed bivariate and multivariate analyses to determine which factors might influence a person's response, they found that age, presence of multimorbidity, health literacy and ethnicity did seem to alter perspectives. The authors concluded that most people are willing to have BBB testing in the primary care setting, however barriers and facilitators to undergoing testing, and response to receiving results, were influenced by factors like age, ethnicity and health literacy. Some of these factors could be overcome (for example, providing more information to support health literacy), other would require greater levels of innovations and enhanced resources.

More information on this study is available here: <https://pubmed.ncbi.nlm.nih.gov/41983466/>

11 MAY:

Fujirebio announces CE mark for Alzheimer's blood test



On 11 May, the diagnostics company Fujirebio announced that its fully automated Lumipulse G pTau 217 Plasma assay had received CE marking under the European Union's In Vitro Diagnostic Medical Devices Regulation (IVDR). The assay enables the quantitative measurement of phosphorylated tau 217 (pTau 217) in human plasma and is designed to support the identification of amyloid pathology associated with Alzheimer's disease (AD).

According to the company, the Lumipulse G pTau 217 Plasma assay is intended to aid healthcare providers to identify people with amyloid pathology associated with AD. The test is indicated for people, aged 50 years and older presenting signs and symptoms of cognitive decline in a specialised care setting.

<https://www.fujirebio.com/en/news-events/fujirebio-announces-ce-marking-of-the-fully-automated-lumipulser-g-ptau-217-plasma>

12 MAY:

American Heart Association convenes Summit on cardiovascular and stroke considerations for anti-amyloid therapies in Valkenburg, the Netherlands

On 11–12 May, the American Heart Association (AHA) convened the Amyloid-Related Imaging Abnormalities (ARIA) Summit: Cardiovascular and Stroke Considerations for Beta-Amyloid Immunotherapy in Alzheimer Disease, held in



Valkenburg, The Netherlands. The event brought together invited experts from neurology, cardiology, emergency medicine, nursing, and neuroradiology to share insights on ARIA and explore considerations for the use of amyloid plaque-lowering monoclonal antibodies and their associated side effects. Our Director for Research, Angela Bradshaw, was among those in attendance.

The programme had a strong focus on vascular neurology and stroke, reflecting the particular risks that heart and blood vessel conditions pose for patients receiving anti-amyloid immunotherapies. Plenary sessions on the first day opened with an overview of the biological mechanisms underlying ARIA, presented by Delphine Boche (University of Southampton), followed by a clinical overview of ARIA, delivered by the Summit co-chair Tara Carlisle (University of Colorado Anschutz Medical Campus). A dedicated session on how vascular factors should inform patient selection and the management of acute events was presented by Mariel Kozberg (Massachusetts General Hospital and Harvard Medical School), a specialist in stroke and diseases of the brain's blood vessels. The afternoon concluded with a panel discussion involving several European experts in the area, including Nikolaos Scarmeas (National and Kapodistrian University of Athens), Federica Agosta (Vita-Salute San Raffaele University, Milan) and Gerhard Ransmayer (Johannes Kepler University, Linz) on developing systems of care and the patient journey for treatment with anti-

amyloid therapies, touching on clinical decision-making, treatment eligibility and risk factor management in their clinics.

On the second day, Angela Bradshaw participated in two working group discussions: one on communicating with patients and families, including shared decision-making around the risks and benefits of immunotherapy, and one on the evaluation and treatment of patients on anti-amyloid therapy who present with acute neurological symptoms, including how emergency department workflows may need to be adapted in this context. The insights gathered at the Summit will inform the development of an ARIA Summit Special Report.

12 MAY:

Roche receives CE mark for new Alzheimer’s disease blood test



On 12 May, Roche announced that it had received a CE Mark for its Elecsys pTau217 blood test. CE marking signifies that the product has been found to meet general safety and performance requirements under the European regulation for *in vitro* diagnostic medical devices (IVDR) and permits the

product to be sold across the EU.

Roche’s Elecsys pTau 217 test, which was developed in collaboration with Eli Lilly and Company, measures the amount of phosphorylated Tau217 (pTau217) in the blood, an indicator of amyloid pathology in the brain. According to the company, a positive test indicates a high likelihood of amyloid pathology, a hallmark of Alzheimer’s disease. A negative result means that clinicians may be able to rule out Alzheimer’s disease pathology, while an intermediate result requires extra testing to be done.

The test is designed to be used across primary and secondary care settings, to rule in or rule out amyloid pathology in people with memory complaints and other signs of cognitive impairment.

For more information, read the Roche press release, here:

<https://www.roche.com/media/releases/med-cor-2026-05-12>

14 MAY:

Biogen announces topline results from Phase II CELIA study of tau-targeting therapy diranersen

On 14 May, the biotechnology company Biogen announced topline results from its Phase II CELIA study evaluating diranersen (BIIB080), an investigational antisense oligonucleotide therapy targeting tau, in people with early Alzheimer’s disease (AD). According to the company, the results provide the first

evidence from a study showing both reduction in Tau pathology and cognitive benefit in people with early AD.

CELIA is a global Phase II randomised, double-blind and placebo-controlled evaluating the efficacy, safety and tolerability of diranersen in people with early AD. The study enrolled 416 participants with mild cognitive impairment due to AD or mild AD dementia. The study evaluated three doses of diranersen administered intrathecally over a 76-week placebo-controlled treatment period. The primary endpoint assessed dose response for change from baseline on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) at week 76, while secondary and exploratory endpoints included additional clinical, biomarker and imaging measures, including cerebrospinal fluid (CSF) tau biomarkers and tau positron emission tomography (PET).

Although the study did not meet its primary endpoint assessing dose response on the CDR-SB scale, pre-specified analyses of cognitive endpoints showed slowing of clinical decline across all studied doses, particularly among participants receiving the lowest dose of diranersen (60 mg administered every 24 weeks). Diranersen also demonstrated robust reductions in tau pathology across all studied doses.

The safety and tolerability profile of diranersen was generally consistent with findings from the earlier Phase Ib study. Following the results, Biogen announced plans to advance diranersen into registrational development and engage with regulators on next steps. Data are expected to be presented at the Alzheimer’s Association International Conference 2026 (AAIC 2026) and other upcoming scientific congresses.


<https://investors.biogen.com/news-releases/news-release-details/topline-results-phase-2-celia-study-diranersen-biib080-first>

19 MAY:

TouchNeurology shares recent AD/PD 2026 highlights on “Advancing early detection, diagnostics and therapeutics across neurodegenerative diseases”

The Alzheimer’s and Parkinson’s Diseases Conference (AD/PD) 2026, recently held in Copenhagen (Denmark) brought together over 5,800 delegates to discuss advances across neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and related disorders.

Key themes emerging from this year’s meeting included the shift towards earlier disease detection, the integration of artificial intelligence (AI) and real-world data, and the development



of novel therapeutic approaches targeting underlying disease biology. TouchNeurology shares some highlighted sessions that took place at AD/PD this year on its online platform (free to register). See: <https://touchneurology.com/insight/ad-pd-2026-highlights-advancing-early-detection-diagnostics-and-therapeutics-across-neurodegenerative-diseases/>

19 MAY:

Neflamapimod as a potential treatment for dementia with Lewy bodies: Insights from the RewinD-LB trial



Dementia with Lewy bodies (DLB) remains an area of high unmet need, with no approved disease-modifying therapies and significant clinical heterogeneity. At the recent AD/PD 2026 conference, new data from the Phase 2b RewinD-LB trial provided further insight into the potential of neflamapimod, a p38α MAP kinase inhibitor, to target key disease mechanisms.

In this Q&A by TouchNeurology, Prof. John-Paul Taylor (Professor of Translational Dementia Research, Northumberland, Tyne and Wear NHS Trust, UK) discusses the trial findings, their implications for understanding DLB biology and the rationale for ongoing Phase 3 development, as well as broader themes in neurodegenerative research, including precision medicine and mechanism-based therapeutic strategies:

<https://touchneurology.com/insight/neflamapimod-as-a-potential-treatment-for-dementia-with-lewy-bodies-insights-from-the-rewind-lb-trial/>

27 MAY:

New article compares pre-diagnostic signs and symptoms of young-onset dementia and late-onset dementia in the general practice

Timely recognition of dementia remains challenging, particularly when symptoms emerge before the age of 65. Compared with dementia onset later in life, younger individuals often present with more diverse and atypical symptoms, which can complicate recognition in primary care and contribute to diagnostic delay. Improving understanding of these early symptom patterns may support earlier identification and referral.



A newly published study led by doctoral researcher Caitlin Hibbs from Maastricht University investigated differences in pre-diagnostic signs and symptoms between people diagnosed with young-onset dementia (YOD) and late-onset dementia (LOD) in general practice. Using data from the Research Network Family Medicine database, the researchers analysed GP records from 88 individuals with YOD and 174 individuals with LOD, examining signs and symptoms documented up to five years before diagnosis.

The study found that, amongst others, affective symptoms, including depressive mood and anxiety, were significantly more common among people with YOD in the years preceding diagnosis. Social indicators, such as worries raised by relatives, relationship problems or work problems, were also more frequently documented in individuals with YOD than LOD up to five years before diagnosis. Interestingly, no significant differences were observed for cognitive symptoms between the two groups. According to the authors, this suggests that distinguishing features of dementia at a younger age may not necessarily be cognitive in nature, but may instead involve broader behavioural, emotional, and social changes.

The researchers note that dementia in younger individuals is often initially attributed to psychiatric conditions, stress, or burnout, partly because dementia is still predominantly associated with older age. Earlier recognition of these non-cognitive symptom patterns in primary care could help reduce diagnostic delays in YOD and improve access to appropriate support and specialist care.

The study was published open access in the Journal of Alzheimer's Disease, and can be read here:

<https://journals.sagepub.com/doi/full/10.1177/13872877261451197>

MEMBERS' NEWS

4 MAY:

Martine Bourqui-Pittet is the new Chief Executive of Alzheimer Switzerland



On 4 May, Dr Martine Bourqui-Pittet, an experienced professional with a background in biochemistry and the healthcare system, took over as Chief Executive of the patient and carer

organisation Alzheimer Switzerland. She succeeds Dr Stefanie Becker, who left the organisation at the end of 2025 after ten years.

The Executive Board of Alzheimer Switzerland has appointed Martine Bourqui-Pittet, a proven expert with a background in natural sciences and health policy and, with this appointment, places its trust in experience in science and the healthcare sector. Until she took up her post, the organisation was led on an interim basis by Deputy Director Daniel Janett, following Stefanie Becker's departure.

Martine Bourqui-Pittet obtained a PhD in biochemistry from the University of Fribourg and has held positions including Head of Department in the Process Development division at the biotech company Crucell. She subsequently moved to the Federal Office of Public Health (FOPH) and most recently headed eHealth Suisse, the federal and cantonal competence and coordination centre.

7 MAY:

Alzheimer Athens introduces a new and dynamic initiative called "Ageless Games"

The "Ageless Games" are a new and dynamic initiative created by Alzheimer Athens to promote active participation and improve the quality of life of people living with dementia who attend its day care centres. The Games took place on 7 May 2026, at the indoor basketball court of the Athens Municipality Organization for Culture, Sports and Youth in Mets. The venue was provided free of charge by the Municipality of Athens, contributing significantly to the success of the event.

The main goal of the Games was to encourage active ageing, entertainment, and social inclusion through team activities that support both physical and mental well-being. The event promoted values such as cooperation, solidarity, respect, and fair play, creating an atmosphere of acceptance and encouragement.

Participants included people with dementia from the association's day care centres, who took part in specially-designed athletic and cognitive activities adapted to their abilities and



needs. Activities included simplified basketball, target exercises, coordination games, memory activities, bowling, golf-croquet, darts, agility ladder exercises, puzzles, goal shooting, and dual-task exercises using cones. Participants also engaged in fun games through "Eligence", a specialised digital platform designed to promote cognitive training through targeted neuroscientific, psychological, and healthcare-backed activities.

Preparation for the Games was supported by specialised healthcare professionals of Alzheimer Athens, mainly fitness trainers and physiotherapists, who designed personalised exercise programmes for each participant. The event also highlighted the importance of exercise, balanced nutrition, and a healthy lifestyle for overall well-being. In total, 200 people participated in the Ageless Games, making the event not only a sports competition, but also a celebration of life, inclusion, and joy.

7 MAY:

Alzheimer Nederland kicks off a World Cup Special of Football Memories

With this year's World Cup coming up, several Dutch football clubs are organising so-called Football Memories World Cup Specials. Alzheimer Nederland has developed a special World Cup edition: a set of conversation cards and other materials designed to give the session a World Cup atmosphere.

Both professional clubs as well as amateur clubs are enthusiastic.

The first football club to join this World Cup Special was the club MVV Maastricht. Some nearly 40 senior citizens with a family member had a pleasant afternoon in the football stadium of their club. With the help of nearly 20 volunteers, an interactive quiz was organised. The volunteers had made a video compilation of six iconic World Cup moments from previous World Cup (semi)finals in which the Dutch team had



played. For instance, Rob Rensenbrink’s shot hitting the post in 1978, Dennis Bergkamp’s goal against Argentina and Robin van Persie’s header against Spain. These sometimes-hilarious video moments were well remembered by most participants.

To create more media attention for this World Cup Special of Football Memories a former radio sport commentator and two former football players were present. One of them, Bert van Marwijk (pictured – ‘then and now’) was the Dutch national coach at the 2010 World Cup. The other Boudewijn Zenden played at the 1998 World Cup.

“Football Memories” is a regular programme run by Alzheimer Nederland. The event on 7 May was made possible with extra funds from the “VriendenLoterij” and with the help of Collaborating Health Funds who promote more peer support.

Over the next two years, Alzheimer Nederland aims to encourage a further 20 new football clubs to organise regular Football Memories sessions, specifically for older people, those with mild memory problems and those with dementia. The materials are also available to all the other 39 football clubs in the Netherlands participating in the Football Memories programme.

15-16 MAY:

Accessibility Must Include Dementia: “Dementia Lithuania” participates in the ACCESSUS Exhibition



On 15-16 May, the association “Dementia Lithuania” participated in the first National Accessibility and Assistive Technology Exhibition ACCESSUS — an important event bringing together organisations, professionals, innovators, policymakers, and communities working towards a more accessible and inclusive society.

The exhibition highlighted how accessibility solutions are essential across all areas of life, including public spaces, healthcare, mobility, employment, education, culture, and community participation. ACCESSUS was initiated by Algirdas Mameniškis and the company Eurogama, in collaboration with

partner organisations, including the Agency for the Protection of the Rights of Persons with Disabilities and many other organisations committed to strengthening accessibility and inclusion in Lithuania.

The event created a valuable platform to reaffirm dementia as one of the leading causes of disability among older people and to ensure that dementia is included within the national accessibility conversation. “Too often, accessibility discussions focus primarily on physical disability, while the experiences of people living with dementia and other cognitive changes remain overlooked”, - said the president of “Dementia Lithuania”, Ieva Petkutė. Here insights were echoed by Rita Matulienė, who is caring for her mother: “Dementia significantly affects a person’s ability to navigate environments, access services, communicate, and participate fully in everyday and community life”.

Including dementia in events such as ACCESSUS is therefore especially important. People living with dementia and their families need accessible information, supportive and dementia-inclusive environments, understanding communities, and services adapted to their changing needs. Accessibility must also include cognitive, emotional, and social accessibility.

During the exhibition, the association “Demencija Lietuvoje” presented practical resources developed to support people living with dementia and their caregivers, including “Get to Know Me,” “Steps After Diagnosis,” and “Caring for a Relative with Dementia: A Practical Guide.” The event also provided an important opportunity to introduce the association’s training programmes for professionals and the wider public, raise awareness about dementia, and highlight the support services available for people living with dementia and their families.

18 MAY:

Hellenic Alzheimer’s Association in Larissa organises “The Adventure of Memory” at the Diachronic Museum



On the occasion of International Museum Day, 18 May 2026, the E.E.N.A.L. (Hellenic Alzheimer’s Association in Larissa), in collaboration with the management of the Diachronic Museum of Larissa, organised an educational programme entitled “Ancient Adventures: The Adventure of Memory.”

The aim of the initiative was to connect the past with the present, bridge contrasts, revive historical events, and reinforce memory. The beneficiaries of E.E.N.A.L. were guided by the Byzantinologist Matina Papanastassoulou through two thematic sections: “Ancient Adventures” and “Discovering the Theatre.” Participants had the opportunity to closely explore all the archaeological findings of the Larissa region, learn about its cultural elements, its ways of life, and the individuals who contributed to the collection of the museum’s cultural wealth. Afterwards, they engaged in an interactive discussion with the Head of Antiquities, Georgios Toufexis, during which they shared personal experiences filled with images, stories, and knowledge about the city of Larissa during the 1950s and 60s. Subsequently, the group of beneficiaries, under the guidance of the scientific coordinator Artemis–Phoebe Nifli, presented a theatrical performance of the emblematic myth of Acrisius, King of Argos. The members of the group improvised roles, wore masks, played musical instruments, and recited dialogues. Through their performance, they highlighted the arrogance of King Acrisius, the fear of losing power, the manipulation of life, and the divine will that ultimately overturns human plans. The presentation of the myth within the museum space by the beneficiaries of E.E.N.A.L. stimulated the mind, connected timeless memories, and shared knowledge, emotions, and valuable lessons.

Furthermore, the active participation of E.E.N.A.L. members showcased extroversion, emphasised the potential and dynamism of vulnerable social groups, and strengthened collaborations with museums. The educational programme concluded with mutual expressions of gratitude and a commemorative photo session.

18 MAY:

A new look for Alzheimer Scotland



Alzheimer Scotland has unveiled a refreshed logo and visual identity as part of a wider brand update following the organisation’s move to a new National Office and change of registered address. The refreshed identity reflects the charity’s continued growth while reinforcing its longstanding commitment to supporting people living with dementia, their families and carers, and working towards a Scotland where nobody faces dementia alone.

The previous “three people” logo had represented Alzheimer Scotland for more than 45 years, symbolising a person living with dementia supported by a carer, who in turn was supported by Alzheimer Scotland. While the organisation’s visual identity is evolving, the values and meaning behind the original logo remain an important part of its history.

Care continues to sit at the heart of Alzheimer Scotland’s work, alongside a broader ambition to help prevent dementia where possible, deliver high-quality support and care, and invest in

the systems and structures that enable brain health and dementia research to thrive. The updated brand identity has been designed to better reflect the organisation’s strategic priorities of Prevent, Care and Cure, while reinforcing its position as Scotland’s leading dementia charity.

The new logo was developed with input from people living with dementia to help create an identity that is more dementia friendly, relatable and representative of the communities Alzheimer Scotland supports today and in the future.

Alzheimer Scotland is retaining its distinctive purple brand colour while introducing an updated colour palette to improve flexibility and readability across digital and printed materials. The refreshed design aims to make information clearer and more accessible for people engaging with the charity’s services and wider work.

Although the organisation’s appearance is changing, its purpose remains the same: Alzheimer Scotland remains committed to supporting people living with dementia, their families and carers, and ensuring that nobody faces dementia alone.

19 MAY:

Students at Tallinn University organise experience cafés to support people affected by dementia

Students from Tallinn University, in cooperation with



the NGO Elu Dementsusega (“Life with Dementia”), have organised a series of experience cafés aimed at supporting people affected by dementia and promoting greater awareness in Estonia.

Although experience cafés (often referred to internationally as memory cafés) are well established in many countries, they are still relatively uncommon in Estonia. At the same time, dementia and the need to support both people living with the condition and their caregivers are increasingly recognised. Initiatives of this kind offer opportunities to provide informal, community-based support alongside existing services.

The cafés were organised as part of the university’s ELU (Interdisciplinary Innovation) project, which brings together students from different academic fields to address social challenges collaboratively. In total, three experience cafés were held in Viimsi, Rae Municipality, and Keila. The aim was to provide people with dementia and their loved ones an opportunity to meet, share experiences, and reduce social isolation. Students from disciplines including psychology, social work, journalism, youth work, and health management participated in the project. Working in cooperation with the NGO, they designed and implemented activities suitable for people with different needs and abilities. Prior to the events, students familiarised themselves with relevant research and practical approaches to ensure that the cafés would be accessible, supportive, and appropriate for participants.

Each café offered a programme of low-threshold activities designed to encourage engagement and interaction. These included games such as bingo, creative tasks, board games, and reminiscence-based activities using familiar objects and images. In some settings, a themed corner with vintage items was used to support conversation and recall. Participants were also offered refreshments, contributing to a relaxed and welcoming environment. In addition, some cafés included informal opportunities for relatives and caregivers to exchange experiences and receive practical information.

Participation numbers across the three events were modest. However, organisers observed that smaller group sizes supported a calm atmosphere and allowed for more individual interaction. The outcomes of the cafés were therefore reflected not only in attendance, but also in the quality of engagement and the opportunity for participants to connect with others in similar situations.

The project also contributed to the students' learning experience by increasing their understanding of dementia and its impact on daily life. At the same time, it highlighted the role of community-based initiatives in complementing formal services and creating more inclusive social environments.

Overall, the experience cafés demonstrated that relatively small-scale initiatives can provide meaningful opportunities for social interaction, information-sharing, and mutual support for people affected by dementia and their families.

NGO Life with Dementia would like to thank Marten Sestverk for providing valuable input and an overview of the initiative.

20 MAY:

Alzheimer Polska receives prestigious honorary award from Ombudsman for its long-standing fight for the dignity, safety, and rights of people living with dementia and their families



On 20 May 2026, an incredibly moving and historic ceremony took place in Warsaw. The Ombudsman honoured Alzheimer Polska (Alzheimer Poland) with a prestigious honorary award. This is the highest distinction, awarded for the organisation's long-standing fight for the dignity, safety, and rights of people

living with dementia and their families. The Ombudsman called the Alzheimer Polska movement in Poland "the guardian and defender of human dignity."

Alzheimer Polska commented:

"This distinction brings us all great pride, but also a great commitment to continue working on behalf of those whose voices are sometimes too little heard. Congratulations to all the organizations involved in supporting people with Alzheimer's. Together, we are building a world of understanding."

22 MAY:

"From local action to shared responsibility" - Federazione Alzheimer Italia celebrates ten years of dementia-friendly community in Italy



More than 70 Communities across 36 provinces in 13 Italian regions, involving 10,000 people with dementia and family members, and 7,700 citizens trained. These are the figures presented at the national conference "Ten Years of Dementia Friendly Communities. From Building Communities to Collective Responsibility", organised by Federazione Alzheimer Italia on 22 May 2026.

Launched in 2016 with the pilot project in Abbiategrasso, near Milan, Dementia Friendly Communities in Italy have, over the past decade, promoted hundreds of initiatives in different areas - including public awareness and training, cultural and recreational activities, and support services- involving more than 700 volunteers and over 220 initiatives co-designed with people living with dementia.

The conference provided an opportunity to showcase experiences developed by several of these Communities, highlighting how supportive relationships and welcoming environments can have a tangible impact on the lives of people with dementia, helping to reduce stigma and isolation. As Susana Inguil, who lives with dementia, explained during her testimony: "It is important to involve people, because that way we feel valued and not excluded".

Throughout the conference, a strong focus emerged on listening and participation, with projects spanning many aspects of

everyday life. Expressive workshops and social theatre activities sit alongside collaborations with universities and technological innovation projects designed to address the needs of people with dementia, relatives, and caregivers. This framework also includes initiatives promoting access to culture - such as the "Un cinema per Amico" project by the Cinema Ariston in Trieste, which received the "Inclusive Realities" award presented by Federazione Alzheimer Italia - as well as cognitive stimulation activities aimed at fostering social connections and reducing isolation.

The conference also featured the presentation of the Dementia Friendly Hospital guidelines, developed for healthcare settings wishing to become "Friends of People with Dementia" and better respond to the specific needs of people living with dementia and their families.

"What we are witnessing is a real change within local communities, with citizens learning to recognise and welcome dementia," said Katia Pinto, President of Federazione Alzheimer Italia. "This is where shared responsibility begins: all of us can and must play our part."

25 MAY:

Local communities seek solutions for a better quality of life for people with dementia in northwestern Bulgaria



In Bulgaria, the topic of dementia is still rarely present in the focus of local policies, especially in more rural areas. Lack of sufficient services, limited awareness, and social isolation remain a serious challenge for people with dementia and their families. These problems are especially prominent in northwestern Bulgaria – a region with an ageing population, high levels of poverty and limited access to support. Additional difficulties are faced by representatives of the Roma community, where dementia often remains hidden due to stigma and lack of access to information.

In response to these challenges, Alzheimer Bulgaria Association and the Community Center "Razvitie – 1892", Byala Slatina, are implementing the project "Strong Communities without Age Barriers". It is supported by the Swiss-Bulgarian Cooperation Programme through the Civic Engagement and Transparency Facility (CETF) 2024-2029. The initiative encourages more active social inclusion of older adults, including people with dementia and their families, in local community life. Within the framework of the project, a Local impact group has been established with participants across different generations and communities. The group is working to identify local problems, raise awareness, and develop a more supportive environment for older adults.

One of the main objectives of the project is to summarise best practice examples and local experience in a Concept for participation and support of people over the age of 65, including people with dementia and representatives of vulnerable groups. This document will subsequently be shared with other municipalities in the country, ensuring national impact of the initiative.



26 MAY:

Dr Fergus Timmons from The Alzheimer Society of Ireland discusses "Why Intimacy Matters in Dementia Care through the Dem-I-CARE Project"



Intimacy and sexuality are fundamental aspects of wellbeing, identity, and relationships throughout life. Yet within dementia care, these topics are often overlooked or avoided - particularly in informal care settings. For people living with dementia and their families, this can lead to uncertainty and a lack of guidance at a time when relationships and needs may be changing.

To address this gap, The Alzheimer Society of Ireland is leading a new three-year Erasmus+ project, Dem-I-CARE: Learning About Intimacy in Dementia Care. The project brings to-

gether partners from Germany, Ireland, Netherlands and Poland to support more informed, open, and compassionate approaches to intimacy in dementia care.

The project was formally launched at a recent transnational meeting hosted in Ireland. Partners used the two-day workshop to align their shared objectives, refine the project plan, and begin development activities across key work packages. They were also pleased to be joined by Dr Hannah Christie (Royal College of Surgeons in Ireland), who provided an insightful overview of intimacy and sexuality in dementia, helping to ground the discussions in both research evidence and lived care experience.

The overall aim of Dem-I-CARE is to develop a culturally sensitive education programme for people impacted by dementia, with a particular focus on intimacy and sexuality in informal

care. Course materials will be co-developed with stakeholders to ensure they are practical, respectful, and responsive to diverse cultural and care contexts.

By increasing knowledge, awareness, skills, and confidence, the project aims to support individuals and families to better navigate this important aspect of wellbeing and ultimately enhance quality of life for people affected by dementia.

Project outputs will be shared widely to foster greater understanding and encourage open dialogue around this often under-discussed but vital topic.

This project is co-funded by the European Union.



DEMENTIA IN SOCIETY

17 APRIL:

French actress Nathalie Baye dies with Lewy body dementia

Legendary French actress Nathalie Baye died on 17 April, at the age of 77, with Lewy body dementia. Nathalie Marie Andrée Baye was a French film, television and stage actress. She began her career in 1970 and appeared in more than 80 films during her life. A ten-time César Award nominee, her four wins were for *Every Man for Himself*, *Strange Affair*, *La Balance*, and *The Young Lieutenant*. Her family reported that her condition had steadily worsened in the months leading up to her passing.



LIVING WITH DEMENTIA

2 MAY:

Trevor Salomon, Chair of the European Dementia Carers Working Group, shares his experience of appearing on television to discuss the UK’s review of its decisions on lecanemab and donanemab

Out of the blue I was contacted in mid-March by Alzheimer’s Society asking if I would be prepared to appear live on ITV lunchtime news. Despite having been previously involved in live television I nevertheless felt that rush of combined anticipation and nerves without even knowing what I was being asked to comment on. It transpired that the news story was about the decision by the UK’s National Institute for Health and Care Excellence (NICE) to look again at the case for lecanemab and donanemab, having previously omitted to factor in the perspective of unpaid family carers, hence my contribution to the news feature.



In June/July 2025, NICE guided that neither of these disease-modifying antibody infusions for early Alzheimer’s should be available on the National Health Service based on cost-effectiveness and clinical benefit. The key reasons given were:

- **Limited benefit:** The slowing of decline was considered modest
- **High cost** of the drug and required monitoring (e.g. regular brain scans)
- **Safety concerns**, including brain swelling or bleeding (ARIA)
- **Service burden:** Delivering the treatment would require major NHS resources (infusions, MRI scans, specialist teams).

The broadcast took place on 20 March. I was allowed to appear via a Zoom link to save me having to travel into central London whilst Kieran Winterburn, Head of National Influencing at Alzheimer’s Society, was present in the studio. In the three and a half minutes we were given (a long time on live TV news) I talked about the drugs giving hope, when previously there was none, and the positive impact they would have on family life by delaying the progress of Alzheimer’s. Kieran spoke about new diagnostics methods able to detect Alzheimer’s so with people knowing sooner about a diagnosis, the importance of these breakthrough drugs speaks for itself, not just for the patient but also for the carer.

Will NICE now change their take on lecanemab and donanemab? Only time will tell.

AE CALENDAR 2026

DATE		
2 JUNE	Guidelines for Persons with Disabilities and First Responders on How to Act in Emergencies (World Bank and the Global Facility for Disaster Reduction and Recovery - GFDRR)	Dianne
2 JUNE	Roundtable on the theme “maintien du lien avec les personnes dans l’ombre concernées par la démence et renforcement des soins informels” hosted by his Majesty King Philippe of the Belgians at the Royal Palace (Brussels, Belgium)	Angela
2 JUNE	Meeting with MEP Adam Jarubas	Jean
3 JUNE	Multi-MeMo Advisory Board meeting	Cindy and Sarah
3 JUNE	FluiDx-AD General Assembly Meeting	Cindy, Faye and Dianne
4 JUNE	EDF ENGO meeting	Owen

4 JUNE	Meeting with Board of European Federation of Neurological Associations (EFNA)	Jean
5 JUNE	Palliative and End-of-life Care Taskforce Group Meeting (INTERDEM)	Dianne and Ana
8 JUNE	Visit of Luxembourg Centre for Systems Biomedicine (LCSB) to the Alzheimer Europe offices (Senningerberg, Luxembourg)	AE team
9-10 JUNE	MindShift – a cross-country mission to reshape Alzheimer’s care (Rome, Italy)	Angela
11-12 JUNE	Siemens Healthineers Clinical Summit (Munich, Germany)	Angela
11 JUNE	COFACE EU Anti-Poverty Webinar	Owen
15 JUNE	Meeting of Fondation Alzheimer (Bertrange, Luxembourg)	Jean
16 JUNE	Meeting with Roche (Basel, Switzerland)	Lukas
18 JUNE	Info session for PREDICTOM Public Ambassador Group	Sarah
18 JUNE	General Assembly of European Public Health Alliance (EPHA)	Jean
18 JUNE	Global Coalition on Aging webinar: Alzheimer’s at a crossroads, closing the innovation and access gap	Angela
25-26 JUNE	36AEC & Anti-stigma Award networking dinner site inspection (Dublin, Ireland)	Isabelle
25 JUNE	PTT Think Tank	Owen
26 JUNE	Lilly Advisory Board (Geneva, Switzerland)	Jean
29 JUNE	European Dementia Carers Working Group meeting (EDCWG)	PI team
29 JUNE	Alzheimer Europe Board meeting (Senningerberg, Luxembourg)	AE Board and staff
30 JUNE	Alzheimer Europe Annual General Meeting (Senningerberg, Luxembourg)	AE Board, members and staff

CONFERENCES 2026-2027

DATE	MEETING	PLACE
27-30 June	12 th Congress of the European Academy of Neurology (EAN) 2026 https://www.ean.org/congress2026	Geneva, Switzerland
1-3 JULY	IPA 2026 International Congress, “Across borders, beyond boundaries: Connecting research, education and practice for better mental health in older people” https://bit.ly/4pbWkuA	Leiden, Netherlands
27-29 October	36 th Alzheimer Europe Conference (#36AEC), “Sláinte: Building momentum in dementia through policy, research and partnership”	Dublin, Ireland
16-20 March 2027	AD/PD 2027 https://adpd.kenes.com/	Barcelona, Spain

36th Alzheimer Europe Conference

Sláinte: Building momentum in dementia through policy, research and partnership

27 - 29 OCTOBER 2026
DUBLIN, IRELAND



Join healthcare professionals, researchers, policy makers and advocates to explore advances in dementia care, research and policy. Connect, contribute and drive progress! **#36AEC**



www.alzheimer-europe.org/conferences